As aforementioned, two metastatic melanoma post-analyses of the clinical trial (#NCT00790010) showed elicitation of humoral responses against galectins (e.g., Gal-1 or Gal-3) in patients with successful combinatorial therapeutic strategies [117,121]. The gene discussed is LGALS3; the disease is metastatic melanoma.